Citations

Clear

2438 citation(s) found for "Ly, Amy".

Lens and solution properties in patients with and without midday fogging
Fogt, Jennifer Swingle , Nau, Cherie B. , Harthan, Jennifer , Nau, Amy , Patton, Kim, Schornack, Muriel , Nau, Cherie, Schornack, Muriel , Fogt, Jennifer Swingle , Shorter, Ellen , Patton, Kimberly

Mayo Clinic

Ophthalmic and Physiological Optics | February 26, 2024 | Volume: 44 | Issue: 4 | Pages: 769-773

10.1111/opo.13293 | PMID 38404141 Get It

Abstract Introduction Midday fogging is a complication of scleral lens (SL) wear that interrupts clear vision during the course of wear. SLs can be made with a variety of gas permeable materials, sizes and surface treatments, and various solutions are available for storing the lenses and for filling them before application on the eye. Many of these factors have been implicated as possible contributors to midday fogging. This study explored the lens and solution properties in habitual SL wearers with and without midday fogging. Methods In this prospective study, 48 habitual SL wearers were evaluated and asked to report whether they experienced midday fogging and if they removed their lenses during the day. They completed the Ocular Surface Disease Index (OSDI), which is a validated tool for dry eye assessment. Lens parameters (material, coatings and diameter) and lens storage and filling solutions were documented. Backward elimination of regression terms evaluated the lens and solution properties in those with and without fogging. OSDI scores were compared using the Mann–Whitney analysis. Results Collectively, the lens properties and solutions accounted for 27.7% of the variance related to midday fogging. None of the factors alone had a significant impact upon midday fogging. The median (interquartile range) OSDI score for those with fogging [37 (35)] was significantly different from those without fogging [10 (15)], with the scores corresponding to severe dry eye and normal eyes, respectively. Conclusion SL wearers with midday fogging exhibited similar symptoms to patients with severe dry eye. Lens and solution characteristics may play a small role in patients with midday fogging, although changing just a single factor is not likely to impact its presence.
Spectral performance evaluation of a second‐generation spectral detector CT
Liu, Leening P. , Shapira, Nadav , Halliburton, Sandra S. , Litt, Harold , Kauczor, Hans‐Ulrich , Noël, Peter B. , Meyer, Sebastian , Perkins, Amy E. , Leiner, Tim , Stiller, Wolfram

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 22, 2024 | Volume: 25 | Issue: 4 | Pages: No page available

10.1002/acm2.14300 | PMID 38386967 Get It

Abstract Purpose The aim of this study was to characterize a second‐generation wide‐detector dual‐layer spectral computed tomography (CT) system for material quantification accuracy, acquisition parameter and patient size dependencies, and tissue characterization capabilities. Methods A phantom with multiple tissue‐mimicking and material‐specific inserts was scanned with a dual‐layer spectral detector CT using different tube voltages, collimation widths, radiation dose levels, and size configurations. Accuracy of iodine density maps and virtual monoenergetic images (MonoE) were investigated. Additionally, differences between conventional and MonoE 70 keV images were calculated to evaluate acquisition parameter and patient size dependencies. To demonstrate material quantification and differentiation, liver‐mimicking inserts with adipose and iron were analyzed with a two‐base decomposition utilizing MonoE 50 and 150 keV, and root mean square error (RMSE) for adipose and iron content was reported. Results Measured inserts exhibited quantitative accuracy across a wide range of MonoE levels. MonoE 70 keV images demonstrated reduced dependence compared to conventional images for phantom size (1 vs. 27 HU) and acquisition parameters, particularly tube voltage (4 vs. 37 HU). Iodine density quantification was successful with errors ranging from ‐0.58 to 0.44 mg/mL. Similarly, inserts with different amounts of adipose and iron were differentiated, and the small deviation in values within inserts corresponded to a RMSE of 3.49 ± 1.76% and 1.67 ± 0.84 mg/mL for adipose and iron content, respectively. Conclusion The second‐generation dual‐layer CT enables acquisition of quantitatively accurate spectral data without compromises from differences in patient size and acquisition parameters.
MD Anderson Long-Term Experience with Management of Temporal Bone Paragangliomas
Raza, Shaan M. , Hanna, Ehab, Brown, Paul D. , McGovern, Susan L. , Gardner, Adam , Gunn, Gary B., Moreno, Amy C. , Jack, Phan, Rubino, Franco , DeMonte, Franco , Gidley, Paul W. , Nader, Marc‐Elie , Su, Shirley Y. , Hanna, Ehab, Gunn, Gary B., Lee, Anna So Youn

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1779986 Get It

Ribosomal quality control factors inhibit repeat-associated non-AUG translation from GC-rich repeats
Tseng, Yi‐Ju , Krans, Amy, Malik, Indranil , Deng, Xiexiong , Yildirim, Evrim , Ovunc, Sinem , Tank, Elizabeth M.H., Jansen‐West, Karen , Kaufhold, Ross, Gómez, Nicolás , Petrucelli, Leonard , Barmada, Sami J. , Todd, Peter K , Barmada, Sami , Kaufhold, Ross T. , Sher, Roger B.

Mayo Clinic

Nucleic Acids Research | February 19, 2024 | Volume: 52 | Issue: 10 | Pages: 5928-5949

10.1093/nar/gkae137 | PMID 38412259 Get It

Abstract A GGGGCC (G4C2) hexanucleotide repeat expansion in C9ORF72 causes amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD), while a CGG trinucleotide repeat expansion in FMR1 leads to the neurodegenerative disorder Fragile X-associated tremor/ataxia syndrome (FXTAS). These GC-rich repeats form RNA secondary structures that support repeat-associated non-AUG (RAN) translation of toxic proteins that contribute to disease pathogenesis. Here we assessed whether these same repeats might trigger stalling and interfere with translational elongation. We find that depletion of ribosome-associated quality control (RQC) factors NEMF, LTN1 and ANKZF1 markedly boost RAN translation product accumulation from both G4C2 and CGG repeats while overexpression of these factors reduces RAN production in both reporter assays and C9ALS/FTD patient iPSC-derived neurons. We also detected partially made products from both G4C2 and CGG repeats whose abundance increased with RQC factor depletion. Repeat RNA sequence, rather than amino acid content, is central to the impact of RQC factor depletion on RAN translation—suggesting a role for RNA secondary structure in these processes. Together, these findings suggest that ribosomal stalling and RQC pathway activation during RAN translation inhibits the generation of toxic RAN products. We propose augmenting RQC activity as a therapeutic strategy in GC-rich repeat expansion disorders.
Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study
Pham, Rachel, Zacharias, Niki M. , Ionescu, Filip , Paravathaneni, Mahati, Marchetti, Kathryn , Sanchez, Darren , Mustasam, Arfa, Sandstrom, Reagan, Vikram, Raghu , Schneider, Amy, Pagliaro, Lance C. , Alifrangis, Constantine , Master, Viraj A. , Hernandez, Cindy, Moses, Kelvin A. , Protzel, Chris, Montgomery, Jeffrey S., Ángel, Martín , Tobias‐Machado, Marcos , Pettaway, Curtis A. , Chahoud, Jad , Nazha, Bassel , Chahoud, Jad , Rose, Kyle , Dhillon, Jasreman , Rao, Priya , Albersen, Maarten , Roussel, Eduard , Nazha, Bassel , Spiess, Philippe E.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | February 17, 2024 | Volume: 116 | Issue: 6 | Pages: 966-973

10.1093/jnci/djae034 | PMID 38366627 Get It

Abstract Introduction This study investigated the efficacy and safety of neoadjuvant chemotherapy for locally advance penile squamous cell carcinoma for which current evidence is lacking. Methods Included patients had locally advanced penile squamous cell carcinoma with clinical lymph node metastasis treated with at least 1 dose of neoadjuvant chemotherapy prior to planned consolidative lymphadenectomy. Objective response rates were assessed using Response Evaluation Criteria in Solid Tumors v1.1. The primary and secondary outcomes were overall survival and progression-free survival, estimated by the Kaplan–Meier method. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events v5.0. Results A total of 209 patients received neoadjuvant chemotherapy for locally advanced and clinically node-positive penile squamous cell carcinoma. The study population consisted of 7% of patients with stage II disease, 48% with stage III, and 45% with stage IV. Grade 2 treatment-related adverse events occurred in 35 (17%) patients, and no treatment-related mortality was observed. Of the patients, 201 (97%) completed planned consolidative lymphadenectomy. During follow-up, 106 (52.7%) patients expired, with a median overall survival of 37.0 months (95% confidence interval [CI] = 23.8 to 50.1 months) and median progression-free survival of 26.0 months (95% CI = 11.7 to 40.2 months). Objective response rate was 57.2%, with 87 (43.2%) having partial response and 28 (13.9%) having a complete response. Patients with objective response to neoadjuvant chemotherapy had a longer median overall survival (73.0 vs 17.0 months, P < .01) compared with those who did not. The lymph node pathologic complete response rate was 24.8% in the cohort. Conclusion Neoadjuvant chemotherapy with lymphadenectomy for locally advanced penile squamous cell carcinoma is well tolerated and active to reduce the disease burden and improve long-term survival outcomes.
Risk of Autoimmune Disease in Research-Identified Cases of Autism Spectrum Disorder: A Longitudinal, Population-Based Birth Cohort Study
Villarreal, Verónica, Katušić, Maja , Myers, Scott M. , Weaver, Amy L. , Voigt, Robert G. , Katusic, Maja Z, Katusic, Maja Z., Nocton, James J.

Mayo Clinic

Journal of Developmental & Behavioral Pediatrics | February 16, 2024 | Volume: 45 | Issue: 1 | Pages: e46-e53

10.1097/dbp.0000000000001232 | PMID 38364086 Get It

ABSTRACT: Objective: Determine the risk of autoimmune disease in research-identified cases of autism spectrum disorder (ASD) compared with referents using a longitudinal, population-based birth cohort. Methods: ASD incident cases were identified from a population-based birth cohort of 31,220 individuals. Inclusive ASD definition based on DSM-IV-TR autistic disorder, Asperger syndrome, and pervasive developmental disorder, not otherwise specified, was used to determine ASD cases. For each ASD case, 2 age- and sex-matched referents without ASD were identified. Diagnosis codes assigned between birth and December 2017 were electronically obtained. Individuals were classified as having an autoimmune disorder if they had at least 2 diagnosis codes more than 30 days apart. Cox proportional hazards models were fit to estimate the hazard ratio (HR) between ASD status and autoimmune disorder. Results: Of 1014 ASD cases, 747 (73.7%) were male. Fifty ASD cases and 59 of the 1:2 matched referents were diagnosed with first autoimmune disorder at the median age of 14 and 17.1 years, respectively. ASD cases had increased risk of autoimmune disease compared with matched referents (HR 1.74; 95% confidence interval [CI], 1.21–2.52). The increased risk was statistically significant among male patients (HR 2.01; 95% CI, 1.26–3.21) but not among the smaller number of female subjects (HR 1.38; 95% CI, 0.76–2.50). Conclusion: This study provides evidence from a longitudinal, population-based birth cohort for co-occurrence of ASD and autoimmune disorders. Thus, children with ASD should be monitored for symptoms of autoimmune disease and appropriate workup initiated.
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma
Szlosarek, Peter W. , Creelan, Ben , Sarkodie, Thomas, Nolan, Luke, Olevsky, Olga, Grosso, Federica , Roy, Amy, Gilligan, David , Kindler, Hedy L. , Papadatos-Pastos, Dionysis, O’Byrne, Kenneth J. , Nowak, Anna K. , Steele, Jeremy, Sheaff, Michael , Shiu, Chiung‐Fang, Kuo, Chih‐Ling, Johnston, Amanda , Group, ATOMIC-Meso Study, Mackean, Melanie , Steele, Nicola , Upadhyay, Sunil , Srivastav, Ratnesh Kumar , Mencoboni, Manlio, Zilembo, Nicoletta, Marinis, Filippo de , Stella, Maria Giulia, Wang, Chin‐Chou , Nowak, Anna K , Taylor, Paul D. , Cortinovis, Diego Luigi , Chitnis, Meenali M. , Ceresoli, Giovanni Luca , Mansfield, Aaron S. , Tsao, Anne S. , Bomalaski, John S. , Zauderer, Marjorie G. , Fennell, Dean Anthony , Group, ATOMIC-Meso Study, Rybkin, Igor I. , Rolfo, Christian , Franks, K. , Shaw, Paul Nicholas , Lind, Michael , John, Thomas , Karapetis, Christos Stelios , Chella, Antonio , Stella, Maria Giulia, Chong, Inn‐Wen

Mayo Clinic

JAMA Oncology | February 15, 2024 | Volume: 10 | Issue: 4 | Pages: 475

10.1001/jamaoncol.2023.6789 | PMID 38358753 Get It

ImportanceArginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in patients with nonepithelioid pleural mesothelioma.ObjectiveTo determine the effect of pegargiminase-based chemotherapy on survival in nonepithelioid pleural mesothelioma, an arginine-auxotrophic tumor.Design, Setting, and ParticipantsThis was a phase 2-3, double-blind randomized clinical trial conducted at 43 centers in 5 countries that included patients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15, 2021, with at least 12 months’ follow-up. Final follow-up was on August 15, 2022. Data analysis was performed from March 2018 to June 2023.InterventionPatients were randomly assigned (1:1) to receive weekly intramuscular pegargiminase (36.8 mg/m2) or placebo. All patients received intravenous pemetrexed (500 mg/m2) and platinum (75-mg/m2 cisplatin or carboplatin area under the curve 5) chemotherapy every 3 weeks up to 6 cycles. Pegargiminase or placebo was continued until progression, toxicity, or 24 months.Main Outcomes and MeasuresThe primary end point was overall survival, and secondary end points were progression-free survival and safety. Response rate by blinded independent central review was assessed in the phase 2 portion only.ResultsAmong 249 randomized patients (mean [SD] age, 69.5 [7.9] years; 43 female individuals [17.3%] and 206 male individuals [82.7%]), all were included in the analysis. The median overall survival was 9.3 months (95% CI, 7.9-11.8 months) with pegargiminase-chemotherapy as compared with 7.7 months (95% CI, 6.1-9.5 months) with placebo-chemotherapy (hazard ratio [HR] for death, 0.71; 95% CI, 0.55-0.93; P = .02). The median progression-free survival was 6.2 months (95% CI, 5.8-7.4 months) with pegargiminase-chemotherapy as compared with 5.6 months (95% CI, 4.1-5.9 months) with placebo-chemotherapy (HR, 0.65; 95% CI, 0.46-0.90; P = .02). Grade 3 to 4 adverse events with pegargiminase occurred in 36 patients (28.8%) and with placebo in 21 patients (16.9%); drug hypersensitivity and skin reactions occurred in the experimental arm in 3 patients (2.4%) and 2 patients (1.6%), respectively, and none in the placebo arm. Rates of poststudy treatments were comparable in both arms (57 patients [45.6%] with pegargiminase vs 58 patients [46.8%] with placebo).Conclusions and RelevanceIn this randomized clinical trial of arginine depletion with pegargiminase plus chemotherapy, survival was extended beyond standard chemotherapy with a favorable safety profile in patients with nonepithelioid pleural mesothelioma. Pegargiminase-based chemotherapy as a novel antimetabolite strategy for mesothelioma validates wider clinical testing in oncology.Trial RegistrationClinicalTrials.gov Identifier: NCT02709512
Gender Disparities in Academic Otolaryngology
Ladlie, Beth L., Case, Hannah F., Perisetla, Priyanka, Austin, Andrew, Craver, Emily C. , Engelberg‐Cook, Erica, Rutt, Amy L. , Engelberg-Cook, Erica , Rutt, Amy L. , Case, Hannah

Mayo Clinic

The Laryngoscope | February 15, 2024 | Volume: 134 | Issue: 5 | Pages: 2144-2152

10.1002/lary.31217 | PMID 38358356 Get It

ObjectiveThe aim was to evaluate representation of women in otolaryngology by examining authorship of research publications and presentations, awards, research grants, leadership, and membership in related organizations.MethodsAuthorship was reviewed from articles published in three otolaryngology journals from 2000 through 2021 to assess the frequency and percentages of female and combination of male and female gender authorship. Gender was evaluated for poster and scientific abstract presentations from 2007 to 2021. Gender representation was reviewed for institutional and society leadership positions, award, and grant recipients in the American Laryngological Society (ALA). Changes in the frequency of female and combination of male and female gender authorship over time were examined with Cochran‐Armitage test for trend.ResultsA total of 16,921 articles, 1,017 presentations, 480 leadership positions, 129 president positions, and 1,137 awards and grants were studied. Women were first authors in 4,153 (24.9%) and last authors in 2,935 (17.8%) published articles for which gender could be determined. Women were first authors in 372 (37.4%) presentations and last authors in 199 (20.2%). Most presentations had a combination of male and female presentation authorship (630, 68%). Women held 69 (14.4%) leadership positions. Of the award and grant recipients, 327 (28.8%) were female. Significant trends were observed for increasing female representation (first authorship publications increased 69.9% from 2000 to 2020, first authorship presentations increased 73.9% from 2007 to 2013, p < 0.001; leadership and awards from 3% to 18% representation, p = 0.02).ConclusionThe proportion of women receiving awards and holding leadership positions is increasing. Efforts that promote gender diversity may further increase representation of women in otolaryngology literature and among the grant and award winners.Level of EvidenceNA Laryngoscope, 134:2144–2152, 2024
Diabetes screening outcomes in youth presenting for paediatric weight management: A report of the Paediatric Obesity Weight Evaluation Registry
Kumar, Seema , King, Eileen, Binns, Helen J. , Christison, Amy L. , Cuda, Suzanne , Joseph, Madeline , Kirk, Shelley, Christison, Amy , Yee, Jennifer K.

Mayo Clinic

Pediatric Obesity | February 1, 2024 | Volume: 19 | Issue: 4 | Pages: No page available

10.1111/ijpo.13102 | PMID 38296252 Get It

SummaryObjectiveRising prevalence of obesity has led to increased rates of prediabetes and diabetes mellitus (DM) in children. This study compares rates of prediabetes and diabetes using two recommended screening tests (fasting plasma glucose [FPG] and haemoglobin A1c [HbA1c]).Study DesignData were collected prospectively from 37 multi‐component paediatric weight management programs in POWER (Paediatric Obesity Weight Evaluation Registry).ResultsFor this study, 3962 children with obesity without a known diagnosis of DM at presentation and for whom concurrent measurement of FPG and HbA1c were available were evaluated (median age 12.0 years [interquartile range, IQR 9.8, 14.6]; 48% males; median body mass index 95th percentile [%BMIp95] 134% [IQR 120, 151]). Notably, 10.7% had prediabetes based on FPG criteria (100–125 mg/dL), 18.6% had prediabetes based on HbA1c criteria (5.7%–6.4%), 0.9% had DM by FPG abnormality (≥126 mg/dL) and 1.1% had DM by HbA1c abnormality (≥6.5%). Discordance between the tests was observed for youth in both age groups (10–18 years [n = 2915] and age 2–9 years [n = 1047]).ConclusionThere is discordance between FPG and HbA1c for the diagnosis of prediabetes and DM in youth with obesity. Further studies are needed to understand the predictive capability of these tests for development of DM (in those diagnosed with prediabetes) and cardiometabolic risk.